


Product Name : AT-56
Cat. No. : PC-38455
CAS No. : 162640-98-4
Molecular Formula : C₂₅H₂₇N₅
Molecular Weight : 397.526
Target : PGE synthase
Solubility : 10 mM in DMSO



Biological Activity

AT-56 is an orally active, selective inhibitor of lipocalin-type prostaglandin D synthase (**L-PGDS**) with K_i of 75 uM, IC₅₀ of 95 uM.

AT-56 inhibited the L-PGDS activity in a competitive manner against the substrate PGH₂ (K_m = 14 μM) with a K_i value of 75 μM but did not inhibit the binding of 13-cis-retinoic acid, a nonsubstrate lipophilic ligand, to L-PGDS.

AT-56 occupied the catalytic pocket, but not the retinoid-binding pocket, of L-PGDS.

AT-56 inhibited the production of PGD₂ by L-PGDS-expressing human TE-671 cells after stimulation with Ca²⁺ ionophore (5 μM A23187) with an IC₅₀ value of 3 uM.

Orally administered AT-56 (<30 mg/kg body weight) decreased the PGD₂ production to 40% in the brain of H-PGDS-deficient mice, without affecting the production of PGE₂ and PGF₂α.

AT-56 also suppressed the accumulation of eosinophils and monocytes in the broncho-alveolar lavage fluid from the antigen-induced lung inflammation model of human L-PGDS-transgenic mice.

References

Daisuke Irikura, et al. *J Biol Chem*. 2009 Mar 20;284(12):7623-30.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com